Interim protocol on dispensing of adrenaline auto-injectors, 150microgram – NHS England

This guidance on the dispensing of adrenaline auto-injectors (150microgram) has been developed for pharmacies and dispensing GP practices. This validation protocol has been developed to ensure consistent practice nationally and to prevent the need for any local re-interpretation.

Antimicrobial resistance: Eleventh Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Health and Social Care Committee

House of Commons Health and Social Care Committee report that identifies that tackling antimicrobial resistance needs to be firmly established as a ‘top five policy priority’ for the government in order to help prevent the virtual loss of worldwide modern

Pharmacy and Dispensing Practice Q&A regarding EpiPen and EpiPen Junior Supply issue – NHS England

This Q&A has been developed for pharmacies and dispensing GP practices about the EpiPen and EpiPen Junior Supply issue.  

Junior Epipen shortage: letter to parents and guardians from Dr Aidan Fowler, National Director of Patient Safety – NHS England

Experts in children’s allergies have developed the advice in this letter to support parents and guardians of children who use Epipen Junior 150mcg.

Burosumab for treating X-linked hypophosphataemia in children and young people: Highly specialised technologies guidance [HST8] – NICE

Evidence-based recommendations on burosumab (Crysvita) for X‑linked hypophosphataemia in children and young people. Burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in

Cabozantinib for untreated advanced renal cell carcinoma: Technology appraisal guidance [TA542] – NICE

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA543] – NICE

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends:  Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as

Price increases for generic medications: Sixty-Second Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Committee of Public Accounts

During 2017, the prices of certain generic medicines purchased by community pharmacies for the NHS increased unexpectedly, affecting an unusually high number of medicines. Although the Department of Health & Social Care (the Department) and its arms-length bodies took action

Surveillance of antimicrobial resistance in Neisseria gonorrhoeae in England and Wales: Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP): Data to May 2018 – Public Health England

Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales provided by GRASP. Public Health England reports annually on drug resistance and decreased susceptibility in gonorrhoea in England and Wales and has twice provided data

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) – NHS England

Updated policy document outlines the arrangements for funding of the use of cobicistat as a booster in treatment of HIV infection (all ages).

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628] – NICE

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder. This guidance replaces NICE interventional procedures guidance on intravesical microwave

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Pharmaceutical waste reduction in the NHS – NHS England

This report seeks to highlight best practice in relation to reducing pharmaceutical waste from local initiatives with the purpose of encouraging others to introduce similar initiatives where appropriate.

Pharmacological management of migraine: (SIGN 155) – Scottish Intercollegiate Guidelines Network

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache. This guideline will be of interest to healthcare professionals in primary and secondary care,

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive

Rezum for treating benign prostatic hyperplasia: Medtech innovation briefing [MIB158] – NICE

The technology described in this briefing is Rezum, which uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia. The innovative aspects are that the company claims that it is quicker to do than

Integrating NHS pharmacy and medicines optimisation into Sustainability and Transformation Partnerships and Integrated Care Systems – NHS England

This document describes the approach for “testing” the principles of a framework for NHS pharmacy and medicines integration within Sustainability and Transformation Partnership (STP) and Integrated Care System (ICS) pilot areas during 2018/19.